Dry Eye Clinical Trial
Official title:
Dry Eye Evaluation System Based on Bioinformatics
Dry eye is a common ocular surface disease of multifactorial etiology characterized by
elevated tear osmolality and inflammation leading to a disrupted ocular surface. The latter
is a risk factor for ocular surface infection, yet overt infection is not commonly seen
clinically in the typical dry eye patient. This suggests that important innate mechanisms
operate to protect the dry eye from invading pathogens. Understand the pathogenesis of dry
eye will be the measure to prevention and treatment of dry eye.
In this essay, the investigators use the data of experiment in the patients with dry eye and
normal, acquire their tear production, tear film stability, and surface damage. The
investigators use weka to calculate the prediction accuracy of the 6 algorithm and select the
best one, optimize the parameters to get the final prediction accuracy.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | January 23, 2020 |
Est. primary completion date | December 23, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 10 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of Dye Eye Exclusion Criteria: - systemic disease (such as diabetes, glaucoma, or systemic collagen vascular disease), ocular disease, a history of tear supplement usage or contact lens wear during the past year,and pregnancy |
Country | Name | City | State |
---|---|---|---|
China | Huaxia Eye Hosptial of Foshan | Foshan | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Huaxia Eye Hospital Group |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | OSDI | The Ocular Surface Disease Index (OSDI; Allergan Inc., Irvine, CA)consists of a 12-item questionnaire and is used to assess dry eye disease; the OSDI questions are drawn from three different categories: vision-related functions, ocular symptoms and environmental triggers. The OSDI is scored on a 4-point scale from 0 (indicating no problems) to 4 (indicating a significant problem). Responses to all of the questions are combined to generate a composite OSDI score that ranges from 0 to 100, with higher OSDI scores representing greater disability. Subjects were asked questions regarding the dry eye symptoms that they experience. | up to 2 months | |
Primary | Schirmer I test | The Schirmer I test (SIT) without anesthesia for tear secretion function was conducted by placing a 30-mm sterile Schirmer Tear Test strip into the junction of the middle and lateral thirds of the inferior fornix of each eye for 5 minutes. The wet portion of the strip was subsequently measured, with lower scores indicating less tear production. | up to 2 months | |
Primary | Fluorescein staining | The cornea was divided into upper, lower, nasal, temporal and central zones. Superficial punctate keratopathy (SPK) in the cornea was scored from 0 to 3 in each area. Where 0 indicated no staining in the cornea; 1,<5 punctate stains; 2,5-10 punctate stains; and 3,>10 or filamentous staining detected. The total score was recorded by adding the scores of the five zones for each eye (range: 0-15). | up to 2 months | |
Primary | Noninvasive Tear Breakup Time | Noninvasive Tear Breakup Time (NI-TBUT) measurements of subjects' eyes were obtained by Keratograph 5. At the start of the recording, the patients were asked to blink three times and then keep their eyes open as long as possible. Irregularities in the reflected image indicated the instability of the tear film. Meanwhile, the examination was recorded on video and a single eye of each subject was assessed three times. All the tests were performeded the same temperature and humidity conditions. | up to 2 months | |
Secondary | Tear meniscus height | Tear meniscus height was also performed by the Keratograph 5 and the image of tear meniscus height was obtained by the instrument. The observer measured the tear meniscus height the center of the lower lid margin. This evaluation was taken three times and the average value was recorded. | up to 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A | |
Completed |
NCT01718028 -
The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects
|
N/A |